Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.

Frontiers in immunology - 1 Jan 2026

Kim Kyoo Hyun, Han Mina, Park Geon Woo, Hong Min Hee, Kim Gamin, Lee Brian Hyohyoung, Son Wonrak, Kim Jaehyung, Go Seokhyeong, Kim Jeongah, Kelly Geoffrey, Nie Kai, Kim-Schulze Seunghee, Merad Miriam, Kim Sangwoo, Kim Chang Gon, Kim Hyun Je, Kim Hye Ryun

Abstract excerpt

Background: Non-small cell lung cancer (NSCLC) patients with oncogenic driver mutations such as EGFR, ALK or ROS1 (mutant-type [MT]) exhibit poor responses to PD-1/PD-L1 immune checkpoint inhibitors (ICIs) compared to wild-type (WT) patients. The mechanisms underlying this limited response to ICIs in MT patients remain unclear. This study aimed to identify key immune biomarkers and elucidate immune cell dynamics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to CD8-Positive T-Lymphocytes

Share to Drug Resistance, Neoplasm

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 42292481
DOI: 10.3389/fimmu.2026.1829816
PMCID: PMC13260270

Genes

CXCR3
CD4
ALK
CD27
EGFR
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.PMID 42292481Read ↗

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.Semantic proximity Read ↗

A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancerSemantic proximity Read ↗

Blood-based Genomic and Cellular Determinants of Response to Neoadjuvant PD-1 Blockade in Patients with Non-Small-Cell Lung CancerSemantic proximity Read ↗

Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.Semantic proximity Read ↗

Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer.Semantic proximity Read ↗

Single cell profiling of bronchoalveolar immune cells in checkpoint inhibitor-related pneumonitisSemantic proximity Read ↗

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancerSemantic proximity Read ↗

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read ↗

Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers studySemantic proximity Read ↗

AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.